Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 5
1987 5
1988 2
1989 6
1990 3
1991 2
1992 6
1993 15
1994 2
1995 2
1996 2
1997 3
1998 5
1999 9
2000 9
2001 12
2002 20
2003 13
2004 19
2005 19
2006 26
2007 38
2008 23
2009 16
2010 16
2011 30
2012 29
2013 18
2014 21
2015 23
2016 24
2017 26
2018 27
2019 38
2020 30
2021 43
2022 25
2023 16
2024 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

579 results

Results by year

Filters applied: . Clear all
Page 1
Pulmonary fibrosis and type-17 immunity.
Senoo S, Higo H, Taniguchi A, Kiura K, Maeda Y, Miyahara N. Senoo S, et al. Among authors: kiura k. Respir Investig. 2023 Sep;61(5):553-562. doi: 10.1016/j.resinv.2023.05.005. Epub 2023 Jun 23. Respir Investig. 2023. PMID: 37356133 Review.
A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infection.
Ichihara E, Hasegawa K, Kudo K, Tanimoto Y, Nouso K, Oda N, Mitsumune S, Yamada H, Takata I, Hagiya H, Mitsuhashi T, Taniguchi A, Toyooka S, Tsukahara K, Aokage T, Tsukahara H, Kiura K, Maeda Y. Ichihara E, et al. Among authors: kiura k. PLoS One. 2023 Oct 26;18(10):e0287501. doi: 10.1371/journal.pone.0287501. eCollection 2023. PLoS One. 2023. PMID: 37883347 Free PMC article. Clinical Trial.
Managing Lung Cancer with Comorbid Interstitial Pneumonia.
Ichihara E, Miyahara N, Maeda Y, Kiura K. Ichihara E, et al. Among authors: kiura k. Intern Med. 2020 Jan 15;59(2):163-167. doi: 10.2169/internalmedicine.3481-19. Epub 2019 Sep 18. Intern Med. 2020. PMID: 31534086 Free PMC article. Review.
Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K, Fujimoto N, Kozuki T, Aoe K, Kiura K. Hotta K, et al. Among authors: kiura k. Expert Opin Biol Ther. 2020 Feb;20(2):109-114. doi: 10.1080/14712598.2020.1703945. Epub 2019 Dec 16. Expert Opin Biol Ther. 2020. PMID: 31825692 Review.
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Hara N, Ichihara E, Kano H, Ando C, Morita A, Nishi T, Okawa S, Nakasuka T, Hirabae A, Abe M, Asada N, Ninomiya K, Makimoto G, Fujii M, Kubo T, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Hara N, et al. Among authors: kiura k. Transl Lung Cancer Res. 2023 Oct 31;12(10):2098-2112. doi: 10.21037/tlcr-23-99. Epub 2023 Oct 26. Transl Lung Cancer Res. 2023. PMID: 38025818 Free PMC article.
Chemotherapy for lung cancer: still alive!
Kiura K. Kiura K. Jpn J Clin Oncol. 2015 Jul;45(7):609-10. doi: 10.1093/jjco/hyv074. Epub 2015 May 19. Jpn J Clin Oncol. 2015. PMID: 25989990 No abstract available.
Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
Ando C, Ichihara E, Nishi T, Morita A, Hara N, Takada K, Nakasuka T, Watanabe H, Kano H, Nishii K, Makimoto G, Kondo T, Ninomiya K, Fujii M, Kubo T, Ohashi K, Matsuoka KI, Hotta K, Tabata M, Maeda Y, Kiura K. Ando C, et al. Among authors: kiura k. Cancer Sci. 2023 Nov;114(11):4343-4354. doi: 10.1111/cas.15958. Epub 2023 Sep 15. Cancer Sci. 2023. PMID: 37715310 Free PMC article.
Molecular oncology of lung cancer.
Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S. Toyooka S, et al. Among authors: kiura k. Gen Thorac Cardiovasc Surg. 2011 Aug;59(8):527-37. doi: 10.1007/s11748-010-0743-3. Epub 2011 Aug 18. Gen Thorac Cardiovasc Surg. 2011. PMID: 21850578 Review.
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Ninomiya T, Ishikawa N, Kozuki T, Kuyama S, Inoue K, Yokoyama T, Kanaji N, Yasugi M, Shibayama T, Aoe K, Ochi N, Fujitaka K, Kodani M, Ueda Y, Watanabe K, Bessho A, Sugimoto K, Oze I, Hotta K, Kiura K. Ninomiya T, et al. Among authors: kiura k. Lung Cancer. 2023 Oct;184:107349. doi: 10.1016/j.lungcan.2023.107349. Epub 2023 Aug 19. Lung Cancer. 2023. PMID: 37651927 Clinical Trial.
579 results